Cantor Fitzgerald initiated coverage on Replimune
$REPL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald initiated coverage of Replimune with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/20/2025 | Overweight | Cantor Fitzgerald | |
| 8/28/2024 | $17.00 | Buy | ROTH MKM |
| 4/17/2023 | $44.00 | Overweight | Piper Sandler |
| 11/19/2021 | $52.00 | Overweight | Piper Sandler |
| 10/15/2021 | $60.00 | Buy | BTIG Research |
| 8/23/2021 | $55.00 → $49.00 | Outperform | SVB Leerink |
| 8/9/2021 | $56.00 → $55.00 | Outperform | SVB Leerink |
8-K - Replimune Group, Inc. (0001737953) (Filer)
S-3 - Replimune Group, Inc. (0001737953) (Filer)
S-3 - Replimune Group, Inc. (0001737953) (Filer)